• Summit Therapeutics (NASDAQ:SMMT) Earns Buy Rating from Analysts at The Goldman Sachs Group

    المصدر: Buzz FX / 01 مارس 2025 07:51:14   America/New_York


    Summit Therapeutics (NASDAQ:SMMT) Earns Buy Rating from Analysts at The Goldman Sachs Group Written by MarketBeat March 1, 2025 Share Link copied to clipboard. Research analysts at The Goldman Sachs Group assumed coverage on shares of Summi
    Read more...
شارك على،